Compare IIIV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.1M | 806.3M |
| IPO Year | 2018 | 2019 |
| Metric | IIIV | CSTL |
|---|---|---|
| Price | $23.77 | $26.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $33.20 | ★ $47.17 |
| AVG Volume (30 Days) | 392.0K | ★ 422.3K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $9.05 | $2.10 |
| Revenue Next Year | $8.07 | $12.63 |
| P/E Ratio | $1,176.50 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $19.89 | $14.59 |
| 52 Week High | $33.97 | $44.28 |
| Indicator | IIIV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 29.30 |
| Support Level | $22.51 | $21.77 |
| Resistance Level | $27.02 | $34.97 |
| Average True Range (ATR) | 0.81 | 1.68 |
| MACD | 0.32 | -0.12 |
| Stochastic Oscillator | 87.65 | 13.48 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.